The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) is a huge mover today! About 2.38M shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 299.24% since March 8, 2016 and is uptrending. It has outperformed by 289.92% the S&P500.
The move comes after 6 months negative chart setup for the $2.83 billion company. It was reported on Oct, 11 by Barchart.com. We have $48.87 PT which if reached, will make NASDAQ:SRPT worth $254.70 million less.
Analysts await Sarepta Therapeutics Inc (NASDAQ:SRPT) to report earnings on November, 3. They expect $-1.31 EPS, down 4.80% or $0.06 from last year’s $-1.25 per share. After $-1.34 actual EPS reported by Sarepta Therapeutics Inc for the previous quarter, Wall Street now forecasts -2.24% EPS growth.
Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage
Out of 19 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 11 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 58% are positive. Sarepta Therapeutics has been the topic of 49 analyst reports since August 5, 2015 according to StockzIntelligence Inc. SunTrust downgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) on Friday, August 7 to “” rating. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, September 28. Wedbush upgraded the shares of SRPT in a report on Tuesday, June 7 to “Outperform” rating. The firm earned “Market Perform” rating on Thursday, April 21 by William Blair. The firm earned “Neutral” rating on Monday, September 19 by SunTrust. The firm earned “Sector Perform” rating on Tuesday, January 19 by RBC Capital Markets. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned “Neutral” rating by Piper Jaffray on Monday, January 18. PiperJaffray upgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) on Monday, September 19 to “Overweight” rating. The company was upgraded on Tuesday, September 20 by Cowen & Co. The company was maintained on Wednesday, August 26 by TH Capital.
According to Zacks Investment Research, “Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.16 in 2016 Q2. Its up 0.32, from 0.84 in 2016Q1. The ratio increased, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
Hightower Advsrs Llc has 0.01% invested in the company for 38,957 shares. Blackrock Japan Company has invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Emerald Mutual Fund Advisers Trust has 0.26% invested in the company for 247,086 shares. Proshare Advsrs Ltd Liability Company holds 39,296 shares or 0.01% of its portfolio. Jefferies Group Ltd Liability holds 0.06% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 685,629 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 1,063 shares or 0% of their US portfolio. The New York-based Bnp Paribas Arbitrage Sa has invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Utd Financial Advisers Lc has invested 0.01% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Gilder Gagnon Howe And Limited Com holds 0.01% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 17,990 shares. Creative Planning holds 0.01% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 65,700 shares. Prentiss Smith And last reported 410 shares in the company. Blackrock Fund Advsrs, a California-based fund reported 1.61M shares. Dekabank Deutsche Girozentrale holds 24,733 shares or 0.01% of its portfolio. Royal Bancorp Of Canada has 0% invested in the company for 4,006 shares. Voya Investment Management Ltd holds 0% or 18,231 shares in its portfolio.
Insider Transactions: Since September 14, 2016, the stock had 0 insider buys, and 7 selling transactions for $7.44 million net activity. Kaye Edward M. MD had sold 40,179 shares worth $2.41M on Thursday, September 22. Aphale Jayant sold 35,000 shares worth $1.75M. Howton David T also sold $420,000 worth of Sarepta Therapeutics Inc (NASDAQ:SRPT) shares. Ruff Shamim had sold 7,311 shares worth $438,660 on Thursday, September 22.
More important recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: Fool.com which released: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.” on October 10, 2016, also Fool.com published article titled: “Here’s Why Sarepta Therapeutics, Inc’s Stock is Jumping Again”, Fool.com published: “Here’s Why Sarepta Therapeutics Inc. is Falling Today” on September 15, 2016. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) was released by: Fool.com and their article: “Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc” with publication date: September 28, 2016.
SRPT Company Profile
Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.